|

ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients

RECRUITINGSponsored by National Taiwan University Hospital
Actively Recruiting
SponsorNational Taiwan University Hospital
Started2025-12-08
Est. completion2027-10-31
Eligibility
Age18 Years – 99 Years
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07322627

Summary

Alcohol consumption, smoking, and betel nut chewing have been proven to be closely associated with the risk of esophageal cancer (EC). Recent studies have shown that alcohol-related detoxification genes in the ALDH family influence individual susceptibility to esophageal cancer. Aldehyde dehydrogenase 2 (ALDH2) is one of the most important enzymes in the ALDH family, involved in the metabolism of alcohol, acetaldehyde, and environmental aldehydes in the human body. We hypothesize that functional variations in ALDH2 may have a significant impact on the survival of esophageal cancer patients. This study aims to investigate the correlation between ALDH2 gene polymorphism and the survival of esophageal cancer patients.

Eligibility

Age: 18 Years – 99 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Patients who have been pathologically confirmed to have esophageal cancer and who have previously signed consent forms indicating their willingness to provide remaining samples for subsequent studies.

Exclusion Criteria:

* Female patients or patients younger than 18 years old

Conditions2

CancerEsophageal Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.